MOLECULAR APPROACHES TO CANCER-THERAPY

被引:11
作者
ISRAEL, MA
机构
[1] University of California at San Francisco, San Francisco
来源
ADVANCES IN CANCER RESEARCH, VOL 61 | 1993年 / 61卷
关键词
D O I
10.1016/S0065-230X(08)60955-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This chapter discusses the proposed molecular approaches to cancer therapy. Cancer arises as a series of molecular alterations that converge to give the cell malignant properties. The genes closely associated with the development of cancer encode products whose activities are easily reconciled with the malignant phenotype of cancer cells. The ability to characterize tumors at the molecular level and to use modern biological and chemical technologies to identify and develop novel molecules of therapeutic potential has opened several possible avenues for the development of new therapeutic modalities. The molecular approaches used are novel antineoplastic agents, modern immunotherapy, and the therapeutic repair of oncogenic genetic lesions. Most antineoplastic agents interact with DNA in a manner that inhibits the replication of the tumor cell genome. Modern immunotherapy for cancer or biologic therapy has both active and passive approaches. Drugs that target specific molecules and gene therapy are divergent approaches to the treatment of cancer. Gene therapy involves the introduction of new genetic information into cells. Gene therapy offers the possibility for novel approaches to the development of tumor vaccines. © 1993, Academic Press Inc.
引用
收藏
页码:57 / 85
页数:29
相关论文
共 139 条
[61]   TYRPHOSTINS - POTENTIAL ANTIPROLIFERATIVE AGENTS AND NOVEL MOLECULAR TOOLS [J].
LEVITZKI, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (05) :913-918
[62]   MONOCLONALITY OF HUMAN B-CELL LYMPHOMAS [J].
LEVY, R ;
WARNKE, R ;
DORFMAN, RF ;
HAIMOVICH, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1977, 145 (04) :1014-1028
[63]   HIGH-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA IN COMBINATION WITH INTERFERON-GAMMA AND MELPHALAN IN ISOLATION PERFUSION OF THE LIMBS FOR MELANOMA AND SARCOMA [J].
LIENARD, D ;
EWALENKO, P ;
DELMOTTE, JJ ;
RENARD, N ;
LEJEUNE, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :52-60
[64]   SPECIFIC HYBRIDIZATION ARREST OF DIHYDROFOLATE-REDUCTASE MESSENGER-RNA INVITRO USING ANTISENSE RNA OR ANTISENSE OLIGONUCLEOTIDES [J].
MAHER, LJ ;
DOLNICK, BJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1987, 253 (01) :214-220
[65]   CONSTRUCTION OF A RETROVIRUS PACKAGING MUTANT AND ITS USE TO PRODUCE HELPER-FREE DEFECTIVE RETROVIRUS [J].
MANN, R ;
MULLIGAN, RC ;
BALTIMORE, D .
CELL, 1983, 33 (01) :153-159
[66]   BIOSYNTHETIC ANTIBODY-BINDING SITES - DEVELOPMENT OF A SINGLE-CHAIN FV MODEL BASED ON ANTIDINITROPHENOL IGA MYELOMA MOPC 315 [J].
MCCARTNEY, JE ;
LEDERMAN, L ;
DRIER, EA ;
CABRALDENISON, NA ;
WU, GM ;
BATORSKY, RS ;
HUSTON, JS ;
OPPERMANN, H .
JOURNAL OF PROTEIN CHEMISTRY, 1991, 10 (06) :669-683
[67]   GTP-BINDING PROTEINS AS ONCOGENES IN HUMAN TUMORS [J].
MCCORMICK, F .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1991, 93 :17-18
[68]   A CLINICAL-TRIAL OF ANTI-IDIOTYPE THERAPY FOR B-CELL MALIGNANCY [J].
MEEKER, TC ;
LOWDER, J ;
MALONEY, DG ;
MILLER, RA ;
THIELEMANS, K ;
WARNKE, R ;
LEVY, R .
BLOOD, 1985, 65 (06) :1349-1363
[69]   A DERIVATIVE OF STAUROSPORINE (CGP-41-251) SHOWS SELECTIVITY FOR PROTEIN-KINASE C INHIBITION AND INVITRO ANTI-PROLIFERATIVE AS WELL AS INVIVO ANTI-TUMOR ACTIVITY [J].
MEYER, T ;
REGENASS, U ;
FABBRO, D ;
ALTERI, E ;
ROSEL, J ;
MULLER, M ;
CARAVATTI, G ;
MATTER, A .
INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (05) :851-856
[70]  
MICKISCH GH, 1992, BLOOD, V79, P1087